-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Merck announced the second quarter of 2021 financial report on July 29, with total revenue of 22.
029 billion US dollars in the first half of the year, a year-on-year increase of 12%
.
Revenue in the second quarter was approximately US$11.
In terms of product development, Merck continues to advance its oncology product portfolio development plan, and it is expected that more than 90 potential new indications will be approved by 2028
.
Just this month, the US FDA approved the listing of the Merck pneumococcal 15-valent conjugate vaccine Vaxneuvance for the prevention of Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, and 9V in adults over 18 years of age.
In the development of COVID-19 therapeutic products, Merck announced in April this year that it would terminate the introduction of the immunomodulator MK-7110 (previously known as CD24Fc) project, and fully promote the development of oral antiviral drug molnupiravir (EIDD-2801/MK-4482)
.
Subsequently, Merck successively announced that it had signed a non-exclusive voluntary license agreement for molnupiravir with an Indian generic drug manufacturer, and reached a procurement agreement for molnupiravir with the US government
Merck expects that its sales in 2021 will increase by 12% to 14%, and its annual revenue will be between 46.